|
Report No. : |
313885 |
|
Report Date : |
25.03.2015 |
IDENTIFICATION DETAILS
|
Name : |
KARACHI
PHARMACEUTICAL LABORATORIES |
|
|
|
|
Registered Office : |
S-54, S.I.T.E. Mauripur Road, Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishments : |
1985 |
|
|
|
|
Legal Form : |
Proprietorship Concern |
|
|
|
|
Line of Business : |
engaged in manufacturing & marketing of Pharmaceutical Products |
|
|
|
|
No of Employees : |
98 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Pakistan ECONOMIC OVERVIEW
Decades of internal political
disputes and low levels of foreign investment have led to slow growth and
underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of
output and two-fifths of employment. Textiles account for most of Pakistan's
export earnings, and Pakistan's failure to expand a viable export base for
other manufactures has left the country vulnerable to shifts in world demand.
Official unemployment was 6.6% in 2013, but this fails to capture the true
picture, because much of the economy is informal and underemployment remains
high. Over the past few years, low growth and high inflation, led by a spurt in
food prices, have increased the amount of poverty. As a result of political and
economic instability, the Pakistani rupee has depreciated more than 40% since
2007. The government agreed to an International Monetary Fund Standby
Arrangement in November 2008 in response to a balance of payments crisis.
Although the economy has stabilized since the crisis, it has failed to recover.
Foreign investment has not returned, due to investor concerns related to
governance, energy, security, and a slow-down in the global economy.
Remittances from overseas workers, averaging about $1 billion a month since
March 2011, remain a bright spot for Pakistan. However, after a small current
account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current
account turned to deficit in the following two years, spurred by higher prices
for imported oil and lower prices for exported cotton. Pakistan remains stuck
in a low-income, low-growth trap, with growth averaging about 3.5% per year
from 2008 to 2013. Pakistan must address long standing issues related to
government revenues and energy production in order to spur the amount of
economic growth that will be necessary to employ its growing and rapidly
urbanizing population, more than half of which is under 22. Other long term
challenges include expanding investment in education and healthcare, adapting
to the effects of climate change and natural disasters, and reducing dependence
on foreign donors.
|
Source
: CIA |
KARACHI PHARMACEUTICAL LABORATORIES
|
Registered Address
& Factory |
|
S-54, S.I.T.E. Mauripur Road, Karachi, Pakistan |
|
Tel # |
92 (21) 32354695, 32354696,
32354697, 32354698 |
|
Fax # |
92 (21) 32354700 |
|
Email |
|
a. |
Nature of Business |
engaged in manufacturing
& marketing of
Pharmaceutical Products |
|
b. |
Year Established |
1985 |
|
c. |
National Tax # |
1000354 - 1 |
In Lahore
Subject Concern was
established as a Proprietorship business in 1985
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Saleh Muhammad Memon |
Pakistani |
S-54, S.I.T.E.
Mauripur Road, Karachi |
Business |
Proprietor |
(1) Subject Concern is engaged in manufacture & marketing of Pharmaceutical Products.
(2) It purchases raw material against L/C, T.T. basis
(3) It sells against cash / credit term basis to its local customers.
(4) Its major customers are Distributors, Traders, Pharmacies & Hospitals located in Karachi.
(5) Subject operates from caption leased factory premises of area measuring 2,500 Sq.Yard. which is situated in industrial area.
(6) Subject employs about 98 persons in its set up.
ACOZINE, ASPIRIN, BELLABARBITONE, BENZYL BENZOATE, BINAPLEX,
CALCIUM LACTATE TABS, CARMINATIVE MIXTURE, CEFLEX, CELIMO, CHLOROQUINE,
CHLOROQUINE, CHLORPHENIRAMINE, DIACRON, DIHYDRANIL, EXCOLD, FLOXON, FOLIC ACID, GENTIAN VIOLET,
GRIFULVIN, ICHTHAMOL GLYCERINE, INDACIN, LYSOL, MALAKIL, MAOLAX, MELAMINE,
METRONIDAZOLE, MULTIVITAMIN DROPS, PAINOL, PANDONA, PEMOXIN, PEXOCITRAL,
PEXOCYCLINE, PEXOL, PEXOLECITHINE, PEXOPEN, PEXOVIT, PHENIRAL, PROMETHAZINE
ELIXIR, ROXENOL, RUMATOFEN, SULPHATRAN, TROCIN, VIBRADOXIN, VIBRODOXIN
|
Year |
In Pak Rupees
|
|
2013 |
120,000,000/-
(Estimated) |
The capacity and production of the concern’s plant is indeterminable as it
is multi- product and involves various processes of manufacture.
Mainly at Karachi & Lahore
· Habib Bank Limited, Napier Road Branch, Karachi, Pakistan.
· Habib Bank Limited, S.I.T.E. Branch, Karachi, Pakistan.
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 102.65 |
|
UK Pound |
1 |
Rs. 152.50 |
|
Euro |
1 |
Rs. 110.25 |
· Karachi Chamber of Commerce & Industry.
· Pakistan Pharmaceutical Manufacturers Association.
Subject Concern was established in 1985 and is engaged in
manufacture & marketing of Pharmaceutical Products.
Trade relations are reported as fair. Concern can be considered for normal
business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.20 |
|
UK Pound |
1 |
Rs.92.93 |
|
Euro |
1 |
Rs.68.03 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.